Interference by anti-cancer chemotherapeutic agents in the MTT-tumor chemosensitivity assay

dc.contributor.authorWood, E.J.
dc.contributor.buuauthorUlukaya, Engin
dc.contributor.buuauthorÇolakoğulları, Mukaddes
dc.contributor.departmentBursa Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Biyokimya Anabilim Dalı.tr_TR
dc.contributor.researcheridK-5792-2018tr_TR
dc.date.accessioned2021-07-01T12:56:02Z
dc.date.available2021-07-01T12:56:02Z
dc.date.issued2004
dc.description.abstractBackground: One of the major goals of oncology is to predict the response of patients with cancer to chemotherapeutic agents by employing laboratory methods variously called 'tumor chemosensitivity assays', 'drug response assays', or 'drug sensitivity assays', in vitro. The MTT assay is one of the methods used to predict the drug response in malignancies. However, it may suffer from interference by the anticancer drugs with the MTT assay. Methods: The MTT assay, a colorimetric viability assay, was checked in a cell-free system in terms of its possible chemical interactions with 22 different anticancer drugs. Results: It was found that epirubicine, paclitaxel, doxetaxel, and cisplatin caused a relatively significant increase in absorbance values, resulting in the MTT assay giving rise to false results (untrue increase in viability) although most of the drugs tested did not seem to cause any significant change. Conclusion: It was concluded that before employing the MTT assay, drugs (or any kind of substances) to be included in the assay should be checked first in terms of possible chemical interactions with MTT, otherwise it may be impossible to evaluate the MTT viability assay results correctly.en_US
dc.identifier.citationWood, E.J. vd. (2004). “Interference by anti-cancer chemotherapeutic agents in the MTT-tumor chemosensitivity assay”. Chemotherapy, 50(1), 43-50.tr_TR
dc.identifier.endpage50tr_TR
dc.identifier.issn0009-3157
dc.identifier.issue1tr_TR
dc.identifier.pubmed15084806tr_TR
dc.identifier.scopus2-s2.0-1842840932tr_TR
dc.identifier.startpage43tr_TR
dc.identifier.urihttps://doi.org/10.1159/000077285
dc.identifier.urihttps://www.karger.com/Article/Abstract/77285
dc.identifier.urihttp://hdl.handle.net/11452/20967
dc.identifier.volume50tr_TR
dc.identifier.wos000220811100010tr_TR
dc.indexed.pubmedPubmeden_US
dc.indexed.scopusScopusen_US
dc.indexed.wosSCIEen_US
dc.language.isoenen_US
dc.publisherKargeren_US
dc.relation.collaborationYurt dışıtr_TR
dc.relation.journalChemotherapyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectMTT assayen_US
dc.subjectTumor chemosensitivity assayen_US
dc.subjectAnticancer drugsen_US
dc.subjectInterferenceen_US
dc.subjectChronic lymphocytic-leukemiaen_US
dc.subjectRecurrent ovarian-canceren_US
dc.subjectCell-linesen_US
dc.subjectIn-vitroen_US
dc.subjectLuminescence assayen_US
dc.subjectTetrazolium assayen_US
dc.subjectInvitro assayen_US
dc.subjectVivoen_US
dc.subjectCytotoxicityen_US
dc.subjectSensitivityen_US
dc.subjectOncologyen_US
dc.subjectPharmacology & pharmacyen_US
dc.subject.wosOncologyen_US
dc.subject.wosPharmacology & pharmacyen_US
dc.titleInterference by anti-cancer chemotherapeutic agents in the MTT-tumor chemosensitivity assaytr_TR
dc.typeArticle
dc.wos.quartileQ4 (Oncology)en_US
dc.wos.quartileQ3 (Pharmacology & pharmacy)en_US

Files

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:

Collections